J Drugs Dermatol. 2023 Oct 1;22(10):SF388641s21-SF388641s26. doi: 10.36849/JDD.8641.
Eczema, or atopic dermatitis (AD), is a chronic relapsing skin disease associated with unpredictable flares of erythema, rash, and pruritus. AD arises from a combination of immune system dysregulation and abnormal skin barrier function. Skin barrier support with proper skincare regimens have a central role in management.
This was a multi-center, 12-week in-use study of a skincare regimen in children and adults with mild-to-moderate eczema (6-16) on the Patient-Oriented Eczema Measure (POEM), and ≥2 flares within 3 months prior to screening. The regimen included Itch Relief Gel, Eczema Soothing Lotion, and Flare Relief Cream. Efficacy assessments included POEM, ItchyQuant, Eczema Area and Severity Index (EASI), Quality of Life and digital photography, along with gathering of adverse events and cutaneous tolerability.
34 subjects completed the study. In 12 weeks, mean POEM scores improved from 9.7 to 5.3, and EASI scores improved by 17.9% (P<0.05 vs baseline). Additionally, mean ItchyQuant scores showed that pruritus was significantly improved from 5.4 at baseline to 2.7 at week 12 (P<0.05). The number of flares decreased from 4.2 to 3.2 after 12 weeks of regimen application (P<0.05 vs 12 weeks before baseline). Quality-of-life measures also showed improvement in both children and adults from baseline (P<0.05). There were no related adverse events, the regimen was well tolerated, and participants had positive perceptions of the regimen.
12-week use of this OTC skincare regimen resulted in significant improvements in EASI, POEM, and ItchyQuant scores, a reduced number of flares, and improved quality of life. J Drugs Dermatol. 2023;22:10(Suppl 2):s21-26.
湿疹,又称特应性皮炎(AD),是一种慢性复发性皮肤病,伴有红斑、皮疹和瘙痒的不可预测发作。AD 是由免疫系统失调和皮肤屏障功能异常共同引起的。通过适当的皮肤护理方案来支持皮肤屏障功能,在治疗中起着核心作用。
这是一项多中心、12 周的在使用研究,评估了一种皮肤护理方案在患有轻度至中度湿疹(6-16 岁)的儿童和成人中的疗效,这些患者在筛选前 3 个月内有 ≥2 次发作。该方案包括止痒凝胶、湿疹舒缓乳液和缓解乳膏。疗效评估包括患者导向的湿疹测量(POEM)、瘙痒量化评分、湿疹面积和严重程度指数(EASI)、生活质量和数字摄影,以及不良事件和皮肤耐受性的收集。
34 名受试者完成了研究。在 12 周内,POEM 评分从 9.7 分改善至 5.3 分,EASI 评分改善了 17.9%(P<0.05 与基线相比)。此外,平均 ItchyQuant 评分表明瘙痒从基线时的 5.4 分显著改善至 12 周时的 2.7 分(P<0.05)。在使用该方案 12 周后,发作次数从 4.2 次减少至 3.2 次(P<0.05 与基线 12 周相比)。儿童和成人的生活质量评分也从基线时开始改善(P<0.05)。无相关不良事件,该方案耐受性良好,参与者对该方案的评价积极。
使用这种 OTC 皮肤护理方案 12 周,可显著改善 EASI、POEM 和 ItchyQuant 评分,减少发作次数,提高生活质量。J 皮肤病药物杂志。2023;22:10(增刊 2):s21-26。